Experience

iTeos Therapeutics

• United States
• Biotechnology Research
• 100 - 200 Employee

• Director - Project Head EOS-984

  • Jul 2022 - Present

  Brussels, Brussels Region, Belgium

• Associate Director - Head Preclinical Immunology

  • Apr 2021 - Aug 2022

  Walloon Region, Belgium Project Lead of the first-in-class EOS100xxx program.

• Head In Vitro Pharmacology

  • Sep 2018 - Apr 2021

  Gosselies, Belgium • Preclinical Project Leader for the first-in-class EOS100xxx small molecule program. Lead preclinical in vitro and in vivo pharmacology, pharmacodynamic biomarkers and patient stratification strategies, and preclinical safety studies.

• Senior Research Scientist

  • Jan 2018 - Jan 2019

  Gosselies Responsible for the in vitro pharmacology package for the best-in-class A2a receptor antagonist EOS100850 program: • Validation of novel targets in immuno-oncology: characterization of target expression & MoA (setup and implementation of functional assays, protocols & technologies) • Immuno-pharmacology: setup of functional assays for screening of small molecules, lead and candidate identification & characterization, evaluation of mAb and small molecule/mAb combinations in functional… Show more Responsible for the in vitro pharmacology package for the best-in-class A2a receptor antagonist EOS100850 program: • Validation of novel targets in immuno-oncology: characterization of target expression & MoA (setup and implementation of functional assays, protocols & technologies) • Immuno-pharmacology: setup of functional assays for screening of small molecules, lead and candidate identification & characterization, evaluation of mAb and small molecule/mAb combinations in functional assays • Setup and validation of PD biomarker assays for target engagement/efficacy in clinical trial • Involved in translational plan for selection of indications and patients • Writing of Investigator Brochure Daily duties are: • Direct management of (senior) research assistants (3 FTEs) & cross-functional management of postdoc, research scientist & assistants in the A2a team (3.5 FTEs) in a matrix organization • Design, planning & coordination of experiments, and review of raw data & data analyses • Coordination of the in vitro pharmacology meetings for the A2a program • Oral and written reporting of scientific results to project team & stakeholders and at conferences, follow-up of relevant literature and new technologies, writing of study reports • Establish and coordinate interactions with CROs & academia Posters & oral communications: - Houthuys, E. et al. (2018). EOS100850, an insurmountable and non-brain penetrant A2A receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in-class characteristics. - Houthuys, E. et al. (2017). A novel non-competitive and non-brain penetrant adenosine A2A receptor antagonist designed to reverse adenosine-mediated suppression of anti-tumor immunity. Posters presented at AACR 2018 (#10507), AACR 2017 (# 1683), CRI-CIMT-EATI-AACR 2017 (# A141) and invited speaker at BIT’s 10th Annual World Cancer Congress, May 2017.

• Research Scientist - Tumor Immunology

  • Dec 2015 - Dec 2018

  Gosselies



Ghent University - VIB

• Post-doctoral researcher

  • Nov 2012 - Nov 2015

  Zwijnaarde, Belgium Responsible for (i) preclinical efficacy, immunology and safety studies of vaccine candidates against tuberculosis; (ii) evaluation of efficacy and immune responses after immunomodulatory therapy in multiple sclerosis.



Max Planck Institute for Infection Biology

• Research Services
• 1 - 100 Employee

• Staff Scientist

  • May 2010 - Oct 2012

  Berlin Area, Germany Responsible for (i) identification & validation of molecules that regulate the immune response to intracellular pathogens; (ii) identification & validation of immune receptors involved in sensing of and defense against bacterial virulence factors (co-first authorship article in Nature 2014).